My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 353

    1.

    Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT).

    Robins SJ, Rubins HB, Faas FH, Schaefer EJ, Elam MB, Anderson JW, Collins D; Veterans Affairs HDL Intervention Trial (VA-HIT).

    Diabetes Care. 2003 May;26(5):1513-7.PMID: 12716814 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

    Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, Faas FH, Anderson JW.

    Arch Intern Med. 2002 Dec 9-23;162(22):2597-604.PMID: 12456232 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial.

    Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, McNamara JR, Kashyap ML, Hershman JM, Wexler LF, Rubins HB; VA-HIT Study Group. Veterans Affairs High-Density Lipoprotein Intervention Trial.

    JAMA. 2001 Mar 28;285(12):1585-91.PMID: 11268266 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Cost-effectiveness of gemfibrozil for coronary heart disease patients with low levels of high-density lipoprotein cholesterol: the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial.

    Nyman JA, Martinson MS, Nelson D, Nugent S, Collins D, Wittes J, Fye CL, Wilt TJ, Robins SJ, Bloomfield Rubins H; VA-HIT Study Group.

    Arch Intern Med. 2002 Jan 28;162(2):177-82.PMID: 11802751 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    The L162V polymorphism at the peroxisome proliferator activated receptor alpha locus modulates the risk of cardiovascular events associated with insulin resistance and diabetes mellitus: the Veterans Affairs HDL Intervention Trial (VA-HIT).

    Tai ES, Collins D, Robins SJ, O'Connor JJ Jr, Bloomfield HE, Ordovas JM, Schaefer EJ, Brousseau ME.

    Atherosclerosis. 2006 Jul;187(1):153-60. Epub 2005 Oct 10.PMID: 16221474 [PubMed - indexed for MEDLINE]Related articles

    6.

    Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.

    Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J.

    N Engl J Med. 1999 Aug 5;341(6):410-8.PMID: 10438259 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial.

    Robins SJ, Collins D, Nelson JJ, Bloomfield HE, Asztalos BF.

    Arterioscler Thromb Vasc Biol. 2008 Jun;28(6):1172-8. Epub 2008 Mar 20.PMID: 18356553 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Relation of gemfibrozil treatment and high-density lipoprotein subpopulation profile with cardiovascular events in the Veterans Affairs High-Density Lipoprotein Intervention Trial.

    Asztalos BF, Collins D, Horvath KV, Bloomfield HE, Robins SJ, Schaefer EJ.

    Metabolism. 2008 Jan;57(1):77-83.PMID: 18078862 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.

    Nesto RW.

    Am J Cardiovasc Drugs. 2005;5(6):379-87. Review.PMID: 16259526 [PubMed - indexed for MEDLINE]Related articles

    10.

    Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease.

    Hay JW, Sterling KL.

    Pharmacoeconomics. 2005;23(2):133-41.PMID: 15748088 [PubMed - indexed for MEDLINE]Related articles

    11.

    Body weight, plasma insulin, and coronary events with gemfibrozil in the Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT).

    Robins SJ, Collins D, McNamara JR, Bloomfield HE.

    Atherosclerosis. 2008 Feb;196(2):849-55. Epub 2007 Mar 1.PMID: 17335828 [PubMed - indexed for MEDLINE]Related articles

    12.

    High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High--Density Lipoprotein Intervention Trial.

    Boden WE.

    Am J Cardiol. 2000 Dec 21;86(12A):19L-22L. Review.PMID: 11374850 [PubMed - indexed for MEDLINE]Related articles

    13.

    Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol.

    Rubins HB, Robins SJ, Iwane MK, Boden WE, Elam MB, Fye CL, Gordon DJ, Schaefer EJ, Schectman G, Wittes JT.

    Am J Cardiol. 1993 Jan 1;71(1):45-52.PMID: 8420235 [PubMed - indexed for MEDLINE]Related articles

    14.

    Cholesteryl ester transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency: Veterans Affairs HDL Cholesterol Intervention Trial.

    Brousseau ME, O'Connor JJ Jr, Ordovas JM, Collins D, Otvos JD, Massov T, McNamara JR, Rubins HB, Robins SJ, Schaefer EJ.

    Arterioscler Thromb Vasc Biol. 2002 Jul 1;22(7):1148-54.PMID: 12117730 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT).

    Bloomfield Rubins H, Davenport J, Babikian V, Brass LM, Collins D, Wexler L, Wagner S, Papademetriou V, Rutan G, Robins SJ; VA-HIT Study Group.

    Circulation. 2001 Jun 12;103(23):2828-33.PMID: 11401940 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    [Clinical study of the month. Usefulness of increasing HDL cholesterol in secondary prevention of coronary heart disease: results of the VA-HIT study]

    Scheen AJ.

    Rev Med Liege. 1999 Sep;54(9):773-5. French. PMID: 10589275 [PubMed - indexed for MEDLINE]Related articles

    17.

    Targeting low high-density lipoprotein cholesterol for therapy: lessons from the Veterans Affairs High-density Lipoprotein Intervention Trial.

    Robins SJ.

    Am J Cardiol. 2001 Dec 20;88(12A):19N-23N. Review.PMID: 11788126 [PubMed - indexed for MEDLINE]Related articles

    18.

    Insulin resistance syndrome predicts coronary heart disease events in elderly type 2 diabetic men.

    Kuusisto J, Lempiäinen P, Mykkänen L, Laakso M.

    Diabetes Care. 2001 Sep;24(9):1629-33.PMID: 11522711 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    What is the most effective strategy for managing diabetic dyslipidaemia?

    Reasner CA.

    Atheroscler Suppl. 2005 Sep;6(3):21-7. Review.PMID: 16054442 [PubMed - indexed for MEDLINE]Related articles

    20.

    Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial.

    Otvos JD, Collins D, Freedman DS, Shalaurova I, Schaefer EJ, McNamara JR, Bloomfield HE, Robins SJ.

    Circulation. 2006 Mar 28;113(12):1556-63. Epub 2006 Mar 13.PMID: 16534013 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity